Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung.

Jiao, Yuyan; Liu, Ming; Luo, Ningning; Guo, Hao; Li, Jianzhe

Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung.

Jiao, Yuyan; Liu, Ming; Luo, Ningning; Guo, Hao; Li, Jianzhe.

Afiliação

Jiao Y; Department of Oncology, Taian City Central Hospital, Taian, People's Republic of China.
Liu M; Department of Oncology, Taian City Central Hospital, Taian, People's Republic of China.
Luo N; Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, People's Republic of China.
Guo H; Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, People's Republic of China.
Li J; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing, People's Republic of China.

JTO Clin Res Rep ; 1(4): 100079, 2020 Nov.

Article em En | MEDLINE | ID: mdl-34589958

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: JTO Clin Res Rep Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: JTO Clin Res Rep Ano de publicação: 2020 Tipo de documento: Article